Niagen Bioscience (NAGE) announced the launch of its clinician-directed telehealth platform under Niagen Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen from home with the Niagen At-Home Injection Kit. The launch marks Niagen Bioscience’s first direct-to-client access model and introduces at-home subcutaneous administration, eliminating the need for an in-person doctor’s or drug store visit, extending the reach of Niagen Plus beyond clinic visits.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience announces new partnership with Olympia Pharmaceuticals
- Niagen Bioscience collaborates with USP to establish USP monograph
- Niagen announces first cruise ship clinic partnership with OneSpaWorld
- Niagen Bioscience Doubles Share Repurchase Authorization to $20M
- Niagen Bioscience increases share repurchase program to $20M